Carnosic acid attenuates obesity-induced glucose intolerance and hepatic fat accumulation by modulating genes of lipid metabolism in C57BL/6J-ob/ob mice

J Sci Food Agric. 2015 Mar 15;95(4):828-35. doi: 10.1002/jsfa.6973. Epub 2014 Nov 24.

Abstract

Background: Carnosic acid (CA), a major bioactive component of rosemary (Rosmarinus officinalis) leaves, is known to possess antioxidant and anti-adipogenic activities. In this study it was hypothesized that CA would ameliorate obesity-induced glucose intolerence and hepatic fat accumulation, and possible mechanisms are suggested.

Results: It was observed that a 0.02% (w/w) CA diet effectively decreased body weight, liver weight and blood triglyceride (TG) and total cholesterol levels (P < 0.05) compared with the control diet. CA at 0.02% significantly improved glucose tolerance, and hepatic TG accumulation was reduced in a dose-dependent manner. Hepatic lipogenic-related gene (L-FABP, SCD1 and FAS) expression decreased whereas lipolysis-related gene (CPT1) expression increased in animals fed the 0.02% CA diet (P < 0.05). Long-chain fatty acid content and the ratio of C18:1/C18:0 fatty acids were decreased in adipose tissue of animals fed the 0.02% CA diet (P < 0.05). Serum inflammatory mediators were also decreased significantly in animals fed the 0.02% CA diet compared with those of the obese control group (P < 0.05).

Conclusion: These results suggest that CA is an effective anti-obesity agent that regulates fatty acid metabolism in C57BL/6J-ob/ob mice.

Keywords: Rosmarinus officinalis; carnosic acid; fatty acid; glucose tolerance; obesity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abietanes / administration & dosage
  • Abietanes / therapeutic use*
  • Animals
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / therapeutic use*
  • Antioxidants / administration & dosage
  • Antioxidants / therapeutic use
  • Carnitine O-Palmitoyltransferase / chemistry
  • Carnitine O-Palmitoyltransferase / genetics
  • Carnitine O-Palmitoyltransferase / metabolism
  • Dietary Supplements*
  • Fatty Acid Synthases / antagonists & inhibitors
  • Fatty Acid Synthases / genetics
  • Fatty Acid Synthases / metabolism
  • Fatty Acid-Binding Proteins / antagonists & inhibitors
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Gene Expression Regulation, Enzymologic*
  • Glucose Intolerance / etiology
  • Glucose Intolerance / prevention & control*
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control
  • Liver / enzymology
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mice, Inbred C57BL
  • Mice, Mutant Strains
  • Non-alcoholic Fatty Liver Disease / etiology
  • Non-alcoholic Fatty Liver Disease / prevention & control*
  • Obesity / diet therapy*
  • Obesity / metabolism
  • Obesity / pathology
  • Obesity / physiopathology
  • Organ Size
  • Plant Extracts / administration & dosage
  • Plant Extracts / therapeutic use*
  • Stearoyl-CoA Desaturase / antagonists & inhibitors
  • Stearoyl-CoA Desaturase / genetics
  • Stearoyl-CoA Desaturase / metabolism
  • Weight Loss

Substances

  • Abietanes
  • Anti-Obesity Agents
  • Antioxidants
  • Fabp1 protein, mouse
  • Fatty Acid-Binding Proteins
  • Plant Extracts
  • Scd1 protein, mouse
  • Stearoyl-CoA Desaturase
  • Carnitine O-Palmitoyltransferase
  • Fatty Acid Synthases
  • salvin